Inventiva Stock: 6.98% Decline Despite Announcements at AASLD Congress
The biopharmaceutical company's stock closed lower this Thursday, despite several recent communications.
Inventiva's Participation in the AASLD Congress
Inventiva announced on October 7 the presentation of four abstracts at the upcoming American Association for the Study of Liver Diseases (AASLD) Congress, which will be held from November 7 to 11, 2025, in Washington. Among these communications is a comparative study between digital imaging and traditional glass slides for histopathological evaluation in the context of the Phase 3 NATiV3 clinical trial, as well as preclinical data on digital pathology applied to lanifibranor, the company's lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This participation is part of the company's communication dynamics, which also included an analyst and investor event on October 8 to discuss its clinical advancements. Despite these announcements, the stock ended the session on October 9 at €4.20, down 6.98% from the previous day when it was trading at €4.52. The traded volumes accounted for 0.67% of the capital, a moderate level of activity reflecting measured investor interest in a context where the CAC 40 itself lost 0.23%.
Short-Term Correction Phase
This decline is part of a short-term correction phase: over the past week, the stock has seen a cumulative drop of 15.49%, bringing the price below its 50-day moving average, positioned at €4.19. This bearish momentum contrasts, however, with a much more favorable medium and long-term trajectory. Over three months, the stock has gained 52.73%, while over one year, the performance reaches 186.5%, significantly surpassing the CAC 40's 6.91% over the same period. This long-term appreciation is notably due to the progress of the Phase 3 NATiV3 clinical trial, whose recruitment was completed in April 2025 and whose main results are expected in the second half of 2026, as well as the strengthening of the company's financial position thanks to structured financing obtained in October 2024.
Technical Analysis
Technically, the stock price is now just above its short-term support at €4.39, leaving little margin in case of new selling pressure. The Relative Strength Index (RSI) is at 50, a neutral position indicating neither oversold nor overbought conditions, and the MACD, although slightly positive at 0.13, remains below its signal line at 0.17, suggesting a hesitant dynamic. The monthly volatility of 16.19% reflects significant short-term fluctuations, characteristic of a growth stock in an advanced clinical phase. With a beta of 0.37, Inventiva shows relatively low sensitivity to movements in the Parisian market, which may interest investors looking for exposure decoupled from the CAC 40. The Bollinger Bands, ranging from €4.25 to €5.31, frame recent variations and signal a consolidation phase after the strong rise in recent months.
